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Abstract
Objectives: The chemokine receptors CCR2 and CX3CR1 are important in the development of coronary artery
disease. The purpose of this study is to analyze the effect of a novel CCR2 inhibitor in conjunction with CX3CR1
deletion on vascular inflammation.
Methods: The novel CCR2 antagonist MRL-677 was characterized using an in vivo model of monocyte migration.
To determine the relative roles of CCR2 and CX3CR1 in vascular remodeling, normal or CX3CR1 deficient mice
were treated with MRL-677. After 14 days, the level of intimal hyperplasia in the artery was visualized by paraffin
sectioning and histology of the hind limbs.
Results: MRL-677 is a CCR2 antagonist that is effective in blocking macrophage trafficking in a peritoneal
thioglycollate model. Intimal hyperplasia resulting from vascular injury was also assessed in mice. Based on the
whole-blood potency of MRL-677, sufficient drug levels were maintained for the entire 14 day experimental period
to afford good coverage of mCCR2 with MRL-677. Blocking CCR2 with MRL-677 resulted in a 56% decrease in the
vascular injury response (n = 9, p < 0.05) in normal animals. Mice in which both CCR2 and CX3CR1 pathways were
targeted (CX3CR1 KO mice given MRL-677) had an 88% decrease in the injury response (n = 6, p = 0.009).
Conclusion: In this study we have shown that blocking CCR2 with a low molecular weight antagonist ameliorates
the inflammatory response to vascular injury. The protective effect of CCR2 blockade is increased in the presence
of CX3CR1 deficiency suggesting that CX3CR1 and CCR2 have non-redundant functions in the progression of
vascular inflammation.
Background
Atherosclerosis is an inflammatory process that is
initiated by endothelial dysfunction leading to an
increase in adhesiveness of platelets and lymphocytes to
the injured region of the artery[1]. The inflammatory
response continues with the migration of monocyte
derived macrophages, dendritic cells, and a subset of T
cells to the area. Finally, smooth muscle cell migration
and proliferation occurs. Chemokines and their recep-
tors play an important regulatory role for these pro-
cesses and genetic studies have revealed specific
polymorphisms that are associated with coronary artery
disease and carotid artery occlusive disease in man[2,3].
Two chemokine receptors, CX3CR1 and CCR2, have
been widely studied in mouse models of inflammatory
disease. Each receptor has been shown to play a role in
inflammatory cell trafficking. CX3CR1 is expressed on
monocytes, natural killer cells, and a subset of T cells
[4]. CX3CR1 is also found on smooth muscle cells[5].
Its ligand CX3CL1 (fractalkine) is a membrane bound
chemokine that is increased in atherosclerosis[6]. We
have shown that this molecular pair can mediate leuko-
cyte adhesion and migration under physiological flow
conditions in vitro[7]. In addition, using CX3CR1 defi-
cient animals, we have shown that these mice have
decreased macrophage and dendritic cell accumulation
during vascular inflammation and are protected from
intimal hyperplasia in an arterial injury model [8,9].
Similarly CCR2 is also expressed on the majority of
blood monocytes, a subset of T cells, as well as other
leukocytes. CCR2 is responsible for directed cell migra-
tion towards its primary ligand monocyte chemotactic
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protein 1 (MCP-1, CCL2) and can also respond to other
chemokines of the MCP family [10]. Furthermore,
CCR2 deficient animals exhibit a decreased susceptibility
to atherosclerosis and also decreased intimal hyperplasia
following arterial injury[11,12]. These two receptors are
differentially expressed in monocyte subsets across spe-
cies from rodent to man[13]. Recent results show that
monocyte migration following kidney ischemia reperfu-
sion injury is dependent on both CCR2 and CX3CR1
[14]. We hypothesized that CCR2 and CX3CR1 have
non-redundant effects in vascular inflammation and
sought to determine their combined effect in a murine
arterial injury model. Arterial injury induces vessel wall
inflammation by stimulating platelet adherence, leuko-
cyte recruitment, and vascular smooth muscle cell
migration and proliferation. These same cellular
responses are the basis of atherosclerosis and restenosis.
Methods
Monocyte recruitment
Defined pathogen-free female C57Bl/6 mice were pur-
chased from Taconic Farms and housed in a sterile
pathogen-free environment. Monocytes were recruited
to the peritoneal cavity over the course of 3 days follow-
ing a single i.p. injection of 1 ml sterile 10% Brewer’s
thioglycollate medium. Three days after the injection of
thioglycollate, peritoneal exudate cells (PECs) were
lavaged from the mice with two 5 ml washes of warm
Dulbecco’s PBS (without Ca++ and Mg++) containing 5%
fetal calf serum and 10 units/ml heparin. All groups
contained 10 mice. Following lavage, PECs from each
mouse were washed once with Dulbeccos PBS contain-
ing 5% fetal calf serum and the total number of viable
cells was determined microscopically with trypan blue.
FACS analysis was used to determine the total number
of monocytes per mouse by staining with FITC anti F4/
80. MRL-677 [patent: US7230008 B2 Appl. No.
US2004923594A], or an equivalent volume (0.5 ml) of
vehicle (DMSO:Cremophor:Saline, 2:4:94, v:v:v) were
administered by oral gavage at the indicated doses once
a day during the 3 day thioglycollate elicitation.
Affinity of MRL-677 for CCR2 in whole blood
Germ free C57Bl/6 mice obtained from Taconic were
used for the following experiments. Murine blood was
collected by cardiac puncture into tubes containing
EDTA to inhibit clotting. For each sample, blood from
three to four animals was pooled together and diluted 1:1
with cold PBS containing 1 mM EDTA. MRL-677 (100 X
concentration) in DMSO (50 μl) was added to 5 ml of
blood to achieve the desired concentration and these
samples incubated for 1 hour at RT with gentle rotation.
PBMCs were rapidly isolated on Ficoll-Hypaque gradi-
ents (Lympholyte-Mammal Cedarlane laboratories Cat #
CL5120). The buffy coat containing principally mono-
cytes and lymphocytes (PBMCs) was isolated from the
interface layer and transferred to a fresh tube. The med-
ium was aspirated after centrifugation and 5 ml cold RBC
lysis buffer (Sigma, Cat # R7757 155 mM ammonium
chloride in 10 mM Tris-HCl buffer) was added and incu-
bated for 5 min at RT to lyse residual red blood cells.
Cold PBS (without Ca++/Mg++) was added to 10 ml, and
cells harvested by centrifuging at 1200 rpm, for 6 min at
4°C. Cells were resuspended in approximately 0.8 ml cold
binding buffer (50 mM HEPES, pH 7.2; 5 mM MgCl2; 1
mM CaCl2; 0.5% BSA and protease inhibitor cocktail
(Sigma #P8340). An aliquot of these cells was retained to
permit precise cell number determinations. 125I-murine
MCP-1 (mMCP-1) binding to cells was then determined
by standard filtration binding assays. Briefly 120 μl of
binding buffer with 25 μl 125I-mouse MCP-1 (4 × 104
cpm, 40 pM) and 100 μl intact cells (500,000) were incu-
bating for 1 hour at RT. The non-specific binding for
each sample was determined by the inclusion of excess
unlabeled mMCP-1 (200 nM) into an identical reaction
mixture for 1 hour at RT.
Murine vascular injury model
CX3CR1 knockout animals were backcrossed onto the
C57Bl/6 background for 12 generations. Normal wild-
type animals (Jackson laboratories) were used for con-
trols. The femoral artery injury was performed using a
procedure previously described[8]. Briefly, femoral
arteries of 8-12 week old male mice in each experimen-
tal arm were injured by endoluminal passage of an
angioplasty guidewire under general anesthesia. Mice
were recovered and monitored after surgery. 14 days
after injury, the mice were perfused with 4% paraformal-
dehyde for 20 minutes via cannulation of the left ventri-
cle. The hind limbs were then harvested en bloc, fixed
in paraformaldehyde and decalcified. Tissues containing
the femoral artery were embedded in paraffin and cut
into 5 mm sections for histologic and morphometric
analysis.
In animals given MRL-677, the drug was administered
by oral gavage at 30 mg/kg for the first two days of the
protocol and thereafter in feed at an approximate dose
of 15 mg/kg/day throughout the 14 days postoperatively.
Blood levels of the antagonist were measured at times
corresponding to peak (morning) and trough (evening).
Histochemistry
Six to ten sections per femoral artery at 100 μm inter-
vals were stained with hematoxylin and eosin. The sec-
tions from the area with maximal injury response were
further evaluated by staining with the Combined Mas-
son’s elastin (CME) stain to visualize the arterial wall
layers. The area of the vessel lumen, intima, and media
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were measured by computerized morphometry (Image J,
NIH). Intimal hyperplasia was defined as the formation
of a neointimal layer within the internal elastic lamina
(IEL). Data were analyzed by t-test and p < 0.05 was
considered significant.
Immunohistochemistry
The serial sections embedded in paraffin were immu-
nostained to detect the presence of monocytes using
procedures previously described[8]. Briefly, after depar-
rafinization, the slides were treated with 0.3% hydrogen
peroxide to inactivate endogenous peroxidase, washed in
TBS, and antigen retrieval performed by incubating in a
solution containing 0.1% CaCl2 and 0.1% trypsin for 30
minutes at 37C. After washing in TBS and blocking in
10% normal rabbit serum, the sections were incubated
in a 1:250 dilution of F4/80 antibody (Serotec) overnight
at 4C. The following day, the samples were washed in
TBS and incubated in a rat anti mouse biotinylated sec-
ondary antibody (1:100 dilution) for 1 hour. After wash-
ing in TBS, the samples were incubated in streptaviden-
horseradish peroxidase (Peroxidase Vectastain ABC kit,
Vector Labs) for 1 hour at room temperature. The
monocytes were then visualized using 3,3’diaminobenza-
dine (DAB, Sigma, St. Louis, Mo) as a substrate and the
sections were counterstained with Gills solution.
Results
We have previously shown that CX3CR1 knockout mice
display a 58% decrease in intimal hyperplasia in a vascu-
lar injury model relative to wildtype animals [8]. In
order to determine any relationship between the
involvement of CX3CR1 and CCR2 in the inflammatory
response in this model, we tested the effect of a specific
CCR2 antagonist (MRL-677) in CX3CR1 knockout mice.
MRL-677 has a murine whole blood potency (IC50) of
3.2 nM as determined by the ability to block 125I
labeled-mCCL2 binding to peripheral blood mononuc-
lear cells (PBMC) after in vitro whole blood treatment
(Figure 1A). This is consistent with the potency of the
compound to block mCCL2 binding to cells expressing
recombinant mCCR2 (IC50 = 1.8 ± 0.4 nM), with a
slight shift noted in whole blood, likely due to protein
binding. MRL-677 was at least 100-fold more effective
in inhibiting CCR2 compared to other chemokine recep-
tors in standard competition binding experiments: mur-
ine CCR5 (selectivity >200 fold), human CCR1
(selectivity > 5000 fold), CCR3 (selectivity >500 fold),
CCR8 (selectivity >500 fold), CXCR1 (selectivity >5000
fold), CXCR2 (selectivity >5000 fold), and CXCR3
(selectivity >500 fold). Table 1 summarizes the findings.
All assays were performed as competition binding assays
using radioactively labeled chemokine receptor ligands.
To confirm the activity of MRL-677 in vivo, we evalu-
ated its effect of CCR2 blockade on monocyte recruit-
ment in response to inflammation in C57Bl6 mice. The
intraperitoneal administration of thioglycollate evoked a
robust monocyte infiltration to the murine peritoneal
cavity (26 ± 6 × 106 cells) compared to mice without
application of thioglycollate (1 × 106 cells). Administra-
tion of MRL-677 at doses of 3, 10, or 30 mg/kg/day
inhibited monocyte recruitment in the peritoneal cavity
upon thioglycollate stimulation by approximately 49%,
75%, and 89% respectively (Figure 1B). Drug levels of
Figure 1 A) MRL-677 added to murine whole blood at the concentrations indicated inhibited the binding of mCCR2 on PBMCs . Each
point represents the average of three measurements and the error bars represent the standard error of the mean. The potency (IC50) of the
compound was determined to be 3.2 nM (+ 0.1 SE) and was determined by a four parameter fit of the data as shown. B) MRL-677 given orally
inhibits recruitment of monocytes into the peritoneal cavity. The number of monocytes recruited to the peritoneal cavity was quantitated by F4/
80 staining of the cellular exudate on day 3 post-intraperitoneal thioglycollate administration. Oral administration of MRL-677 for the three days
at the doses indicated was able to inhibit monocyte recruitment to the peritoneal cavity.
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MRL-677 assessed at trough for these experiments were
below the limit of detection (<1 nM) 24 hours after 3
and 10 mg/kg/day doses and was 5 nM 24 hours after
the highest dose tested at 30 mg/kg/day. Therefore,
MRL-677 was administered by oral gavage at 30 mg/kg
for the first two days and thereafter in feed at a dose of
~15 mg/kg/day in order to evaluate the effect of inhibit-
ing CCR2 on vascular inflammation in response to
injury. In addition to reducing animal handling and the
stress that accompanies it, the administration of the
drug in feed was anticipated to lead to higher trough
drug levels to ensure complete blockade.
In the vascular injury experiments, we first measured
the blood concentration of MRL-677 everyday for the
complete experimental course of 14 days in both wild-
type and CX3CR1 KO mice. We achieved an average
trough level of 0.43 ± 0.11 μM for wildtype mice and
0.68 ± 0.41 μM for CX3CR1 KO mice. This indicates
that sustained therapeutic drug concentrations consider-
ably greater than those anticipated to give >95% cover-
age of CCR2 based on the mouse whole blood potency
(whole blood IC95 = 0.06 μM, corresponding to 19 fold
the IC50) were achieved during the 14 day treatment.
Then we examined the intimal hyperplasia by measur-
ing the ratio of the area of the intima over the media (I/
M ratio) 14 days after the femoral artery injury proce-
dure. Treatment of wildtype mice with the CCR2
antagonist resulted in 56% reduction in intimal hyper-
plasia compared to wildtype mice without antagonist
treatment (0.482 ± 0.097 vs. 0.213 ± 0.05, p < 0.05) (Fig-
ure 2). In addition, the degree of protection from inti-
mal hyperplasia observed in the normal mice fed the
drug is similar to that seen in CCR2 deficient mice
(0.213 ± 0.05 vs. 0.133 ± 0.084, p = NS). Furthermore,
there was a dramatic reduction in vascular injury
observed in the CX3CR1 KO animals given the CCR2
antagonist (I/M ratio of 0.056 ± 0.017) in which there
was an 88% decrease in the development of intimal
hyperplasia relative to untreated wildtype animals. Thus,
knocking out the CX3CR1 pathway together with block-
ing CCR2 function via MRL-677 significantly decreased
the intimal hyperplasia and this decrease is greater than
inhibiting CCR2 alone (p = 0.009, Figure 3). In order to
determine whether or not monocyte trafficking played a
role in the change in intimal hyperplasia observed, we
performed immunohistochemistry on sections. Figure 4
shows that while monocytes are seen in injured femoral
arteries from wildtype mice, there is a significant
decrease in monocyte numbers in MRL-677 treated ani-
mals. These data suggest that although CX3CR1 and
CCR2 can both influence vascular inflammation and
remodeling, their roles are non-redundant and additive.
Discussion
Both CX3CR1 and CCR2 are important in the develop-
ment of coronary artery disease [15]. These receptors
may play a role in the migration of monocytes and den-
dritic cells to the atherosclerotic plaque as well as in the
proliferation of vascular smooth muscle cells observed
during the vascular remodeling stage. In this study, we
show that the compound MRL-677 is a potent and
effective antagonist for murine CCR2. In a thioglycollate
induced assay of monocyte migration in mice, MRL-677
nearly completely inhibits F4/80+ monocyte migration at
a dose of 30 mg/kg (given as oral gavage) which gave
trough drug levels of 5 nM. However, significant inhibi-
tion of monocyte recruitment was also observed at
doses of 3 and 10 mg/kg during which drug levels fell
below the IC50 of the compound. Administration of the
drug at approximately 15 mg/kg/day in feed resulted in
increased plasma drug levels at trough (PM) with drug
levels reaching average levels over 400 nM. This is likely
due to the fact that the drug is ingested over a pro-
longed period of time which blunts the peak-to-trough
relative to a single oral gavage.
We have also shown that blocking CCR2 with this low
molecular weight antagonist ameliorates the inflamma-
tory response to vascular injury. This finding is consis-
tent with previous results using a CCR2 antibody in a
rhesus model of vascular injury[16]. Therefore targeting
of CCR2 may be a good therapy for reduction of reste-
nosis after angioplasty. However, simultaneous blockade
of the CCR2 and CX3CR1 signaling pathways has an
even greater effect than blockade of either receptor
alone. We have previously published that CX3CR1 defi-
cient mice exhibited a 58% decrease in intimal hyperpla-
sia compared to wildtype animals (p = .0017)[8]. Among
CCR2 antagonist treated animals, the CX3CR1 KO
mouse exhibited a significantly lesser degree of intimal
hyperplasia on drug compared to the wildtype animals
given the drug. This result suggests a complementary
and perhaps synergistic effect on the development of the
vascular inflammatory response of these two chemokine
pathways. Our findings support reports published
recently using atherogenic ApoE -/- mice that were
Table 1 CCR2 Antagonist MRL-677 Competition
IC50 or % inhibition
Murine CCR2 1.8 ± 0.4 nM
Murine CCR5 418 ± 76 nM
Human CCR1 24% @ 10 μM
Human CCR3 No inhibition @ 1 μM
Human CCR8 No inhibition @ 1 μM
Human CXCR1 8% @ 10 μM
Human CXCR2 11% @ 1 μM
Human CXCR3 3% @ 1 μM
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Figure 2 CME stained cross section of mouse femoral artery (a) with no injury and (b)14 days after endoluminal injury in wildtype
mouse, (c) wildtype mouse fed CCR2 antagonist, and (d) CX3CR1 KO mouse fed CCR2 antagonist . IEL is marked by arrows. Note the lack
of a visible intima with the IEL defining the vessel lumen in the uninjured artery (a). The neointima overlies the IEL in the injured animals (b-d).
Figure 3 Shown are the average intimal/media ratios for each experimental arm . Graph depicts the mean ± standard error in each group.
Statistical significance was achieved for differences between WT and WT+MRL-677, as well as between WT+MRL-677 and CX3CR1 KO+MRL-677.
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deficient in both CCR2 and CX3CL1 [17,18]. They show
that there is reduced macrophage accumulation and
atherosclerotic lesion formation in these animals com-
pared to the single knockout mice, suggesting that
CX3CR1 and CCR2 can act independently to promote
monocyte recruitment to the atherosclerotic lesions. It
has been suggested that CCR2 may be important for the
migration of monocytes to the atherosclerotic plaque
while CX3CR1 may play a larger role in the retention of
the monocytes to the lesion[19].
Therefore, our results further imply that CCR2 and
CX3CR1 have independent, non-redundant roles in vas-
cular inflammation and the later stages of coronary
artery disease. Approaches to target both may have
more beneficial effects than targeting each one
separately.
Conclusion
The results of our study indicate that CCR2 and
CX3CR1 act by distinct and non-redundant mechanisms
to mediate vascular inflammation following arterial
injury.
Acknowledgements
We’d like to thank Kathy Lyons for analysis of MRL-677 drug levels, Hong Jin
and Kathleen Sullivan for providing additional information on the affinity of
MRL-677 for mouse CCR2 and Mike Forrest for his assistance with the in vivo
characterization of MRL-677. This work was partly funded by a grant
(5RO1HL077406) from the National Heart Lung and Blood Institute of the
NIH.
Author details
1Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
2Merck & Co. Rahway, NJ, USA. 3Novartis Institutes for Biomedical Research,
Basel, Switzerland.
Authors’ contributions
MJ performed the studies and data analysis, PL aided in the studies and
analysis (vascular injury model). LP, AC, and RP performed studies and data
analysis (monocyte recruitment and whole blood affinity of MRL-677). LY
synthesized and provided MRL-677. MS participated in the study design, JD
participated in the study design, MR performed the surgeries, DP
participated in the study design, and AF performed some experiments and
wrote the manuscript. All authors read and approved the final manuscript.
Competing interests
MS, LP, AC, JD, RP and LY declare that they are current or former employees
of Merck and Company. DP declares that while his involvement in the study
was during his employment at the University of North Carolina, he is
currently an employee of the Novartis Institutes for Biomedical Research.
Received: 5 October 2009 Accepted: 13 September 2010
Published: 13 September 2010
References
1. Ross R: Atherosclerosis–an inflammatory disease. N Engl J Med 1999,
340:115-126.
2. Charo IF, Taubman MB: Chemokines in the pathogenesis of vascular
disease. Circ Res 2004, 95:858-866.
3. Apostolakis S, Baritaki S, Kochiadakis GE, Igoumenidis NE, Panutsopulos D,
Spandidos DA: Effects of polymorphisms in chemokine ligands and
receptors on susceptibility to coronary artery disease. Thromb Res 2007,
119:63-71.
4. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M,
Takagi S, Nomiyama H, Schall TJ, Yoshie O: Identification and molecular
Figure 4 Monocytes within the femoral artery were detected by immunohistochemistry using the F4/80 antibody . A representative
section from wildtype animals and those treated with MRL-677 is shown. The top pair of pictures was counterstained in Gills solution.
Jerath et al. Thrombosis Journal 2010, 8:14
http://www.thrombosisjournal.com/content/8/1/14
Page 6 of 7
characterization of fractalkine receptor CX3CR1, which mediates both
leukocyte migration and adhesion. Cell 1997, 91:521-530.
5. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM, Greaves DR: Smooth
muscle cells in human atherosclerotic plaques express the fractalkine
receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine
fractalkine (CX3CL1). Circulation 2003, 108:2498-2504.
6. Wong BW, Wong D, McManus BM: Characterization of fractalkine
(CX3CL1) and CX3CR1 in human coronary arteries with native
atherosclerosis, diabetes mellitus, and transplant vascular disease.
Cardiovasc Pathol 2002, 11:332-338.
7. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD:
Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte
capture, firm adhesion, and activation under physiologic flow. J Exp Med
1998, 188:1413-1419.
8. Liu P, Patil S, Rojas M, Fong AM, Smyth SS, Patel DD: CX3CR1 deficiency
confers protection from intimal hyperplasia after arterial injury.
Arterioscler Thromb Vasc Biol 2006, 26:2056-2062.
9. Liu P, Yu YR, Spencer JA, Johnson AE, Vallanat CT, Fong AM, Patterson C,
Patel DD: CX3CR1 deficiency impairs dendritic cell accumulation in
arterial intima and reduces atherosclerotic burden. Arterioscler Thromb
Vasc Biol 2008, 28:243-250.
10. Kuziel WA, Morgan SJ, Dawson TC, Griffin S, Smithies O, Ley K, Maeda N:
Severe reduction in leukocyte adhesion and monocyte extravasation in
mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci USA 1997,
94:12053-12058.
11. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in
CCR2-/- mice reveals a role for chemokines in the initiation of
atherosclerosis. Nature 1998, 394:894-897.
12. Roque M, Kim WJ, Gazdoin M, Malik A, Reis ED, Fallon JT, Badimon JJ,
Charo IF, Taubman MB: CCR2 deficiency decreases intimal hyperplasia
after arterial injury. Arterioscler Thromb Vasc Biol 2002, 22:554-559.
13. Geissmann F, Jung S, Littman DR: Blood monocytes consist of two
principal subsets with distinct migratory properties. Immunity 2003,
19:71-82.
14. Li L, Huang L, Sung SS, Vergis AL, Rosin DL, Rose CE Jr, Lobo PI, Okusa MD:
The chemokine receptors CCR2 and CX3CR1 mediate monocyte/
macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int
2008, 74:1526-1537.
15. Schober A: Chemokines in vascular dysfunction and remodeling.
Arterioscler Thromb Vasc Biol 2008, 28:1950-1959.
16. Horvath C, Welt FG, Nedelman M, Rao P, Rogers C: Targeting CCR2 or
CD18 inhibits experimental in-stent restenosis in primates: inhibitory
potential depends on type of injury and leukocytes targeted. Circ Res
2002, 90:488-494.
17. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B,
Merval R, Proudfoot A, Tedgui A, Mallat Z: Combined inhibition of CCL2,
CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and
almost abolishes atherosclerosis in hypercholesterolemic mice.
Circulation 2008, 117:1649-1657.
18. Saederup N, Chan L, Lira SA, Charo IF: Fractalkine deficiency markedly
reduces macrophage accumulation and atherosclerotic lesion formation
in CCR2-/- mice: evidence for independent chemokine functions in
atherogenesis. Circulation 2008, 117:1642-1648.
19. Barlic J, Zhang Y, Foley JF, Murphy PM: Oxidized lipid-driven chemokine
receptor switch, CCR2 to CX3CR1, mediates adhesion of human
macrophages to coronary artery smooth muscle cells through a
peroxisome proliferator-activated receptor gamma-dependent pathway.
Circulation 2006, 114:807-819.
doi:10.1186/1477-9560-8-14
Cite this article as: Jerath et al.: Dual targeting of CCR2 and CX3CR1 in
an arterial injury model of vascular inflammation. Thrombosis Journal
2010 8:14.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jerath et al. Thrombosis Journal 2010, 8:14
http://www.thrombosisjournal.com/content/8/1/14
Page 7 of 7
